Merck discontinues Covid-19 vaccine candidates on grounds of poor performance

Merck said that the review findings of the clinical trials showed that V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen

The post Merck discontinues Covid-19 vaccine candidates on grounds of poor performance appeared first on Pharmaceutical Business review.

This is not a CAPTIS article. Originally, it was published here.